Mazyar Shadman, M.D., M.P.H.@mshadman @fredhutch #Non-HodgkinLymphoma #Cancer #Research Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy

Mazyar Shadman, M.D., [email protected] @fredhutch #Non-HodgkinLymphoma #Cancer #Research Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy

User Photo
Cancer-News

2 months
44 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Mazyar Shadman, M.D., M.P.H. from Fred Hutchinson Cancer Research Center discusses A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.



For more information, click the link below -
https://clinicaltrials.gov/ct2/show/NCT03277729?term=NCT03277729&draw=2&rank=1


OUTLINE:

This is a dose-escalation phase I/II analysis of CD20-specific therapy with CAR T cells.

Patients undergo leukapheresis and, if necessary for disease control, can receive treatment afterward. Patients first undergo intravenous cyclophosphamide (IV). Fludarabine IV can also be given to patients. After 36-96 hours, patients undergo 20-30 minutes of CD20-specific CAR T cell infusion IV.

For about 15 months, patients will be actively involved in the research. The total duration includes the time for the T cells to be generated, the infusion of the T cells, and about 12 months after the infusion of the T cells. Patients are treated for a period of 15 years following the completion of study therapy.

Up Next Autoplay
>